Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pandemic flu H5 mRNA vaccine · 1 trial · 1 indication
Number of participants experiencing immediate AEs
Number of participants experiencing solicited injection site reactions
Number of participants experiencing solicited systemic site reactions
Number of participants experiencing unsolicited AEs
Number of participants experiencing MAAEs
Number of participants experiencing AESIs
Number of participants experiencing SAEs
Number of participants with out-of-range biological test results
| Arm | Type | Description |
|---|---|---|
| Group 1: Low Dose Pandemic flu H5 mRNA vaccine | EXPERIMENTAL | Participants will receive 2 injections of pandemic flu H5 mRNA vaccine 21 days apart (at Day 01 and Day 22) |
| Group 2: Medium Dose Pandemic flu H5 mRNA vaccine | EXPERIMENTAL | Participants will receive 2 injections of pandemic flu H5 mRNA vaccine 21 days apart (at Day 01 and Day 22) |
| Group 3: High Dose Pandemic flu H5 mRNA vaccine | EXPERIMENTAL | Participants will receive 2 injections of pandemic flu H5 mRNA vaccine 21 days apart (at Day 01 and Day 22) |
| Group 4: Placebo | PLACEBO_COMPARATOR | Participants will receive 2 injections of placebo 21 days apart (at Day 01 and Day 22) |
| Name | Type | Description |
|---|---|---|
| Pandemic flu H5 mRNA vaccine | BIOLOGICAL | Pharmaceutical Form: Suspension for injection Route of Administration: Intramuscular (IM) |
| Placebo | OTHER | Pharmaceutical Form: Liquid solution for injection Route of Administration: Intramuscular (IM) |
Inclusion Criteria: * Aged 18 years or older on the day of inclusion. * A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: * Is of non-childbearing potential. To be considered of non-childbearing potential, a femal...
The Pandemic flu H5 mRNA vaccine is an investigational vaccine developed by Sanofi for influenza immunization. It uses mRNA technology to target pandemic H5 influenza. It is in Phase 1 clinical development and has been studied in a completed trial of 276 healthy adults aged 18 years and older in the United States.
Sanofi is developing the Pandemic flu H5 mRNA vaccine. Sanofi trades on the New York Stock Exchange under the ticker SNY. The company is the sponsor of the clinical program evaluating this vaccine candidate.
The Pandemic flu H5 mRNA vaccine is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. It is an investigational vaccine and has not been approved by the FDA.
The Pandemic flu H5 mRNA vaccine has been evaluated in one clinical trial, NCT06727058, titled "Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older." The Phase 1 trial was completed, enrolled 276 participants, and was conducted in the United States.
The Pandemic flu H5 mRNA vaccine is being developed for influenza immunization, specifically against pandemic H5 influenza. It is intended for healthy adults aged 18 years and older. The vaccine remains investigational and is not approved for use.